C12Y 205/01018
Glutathione transferase
Official title: Glutathione transferase (2.5.1.18)
C12Y205/01018 (Glutathione transferase) appears on 65 US grants and 129 published applications in this corpus.
Search patents in C12Y- Granted patents
- 65
- Published applications
- 129
- Assignees
- 70
- Inventors
- 209
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 2 | 2 |
| 2005 | 0 | 4 |
| 2006 | 1 | 5 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 5 |
| 2011 | 3 | 0 |
| 2012 | 2 | 6 |
| 2013 | 2 | 7 |
| 2014 | 1 | 2 |
| 2015 | 2 | 6 |
| 2016 | 4 | 18 |
| 2017 | 3 | 11 |
| 2018 | 6 | 13 |
| 2019 | 9 | 10 |
| 2020 | 7 | 8 |
| 2021 | 2 | 7 |
| 2022 | 9 | 6 |
| 2023 | 4 | 3 |
| 2024 | 2 | 4 |
| 2025 | 0 | 3 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant host cells with improved production of tetraketide derivatives22 Sep 2026US 12,742,189 B2Iptector Assets Aps
- Methods, compositions, and kits for improving pancreatic beta cell viability and treating diseases or conditions related to beta cell destruction20 Jan 2026US 12,527,822 B2City of Hope
- Treatments of oxidative stress conditions18 Jun 2024US 12,011,476 B2University of Vermont and State Agricultural College
- SiRNA structures for high activity and reduced off target12 Mar 2024US 11,926,831 B2Nitto Denko Corporation
- Fusion protein comprising glutathione-s-transferase and protein having binding affinity target cell or target protein, and use thereof19 Dec 2023US 11,844,844 B2Unist (Ulsan National Institute of Science and Technology)
- New high expression and high activity n-glycosidases, methods of production and applications thereof8 Oct 2026US 2026/0308562 A1Centre National de la Recherche Scientifique (CNRS)
- Compositions and methods for enhancing drug resistance in cells10 Sep 2026US 2026/0265712 A1Medici Therapeutics, Inc.
- Sirna structures for high activity and reduced off target27 Aug 2026US 2026/0250686 A1Nitto Denko Corporation
- Recombinant host cells with improved production of tetraketide derivatives27 Aug 2026US 2026/0250728 A1Iptector Assets Aps
- Methods, compositions, and kits for improving pancreatic beta cell viability and treating diseases or conditions related to beta cell destruction25 Jun 2026US 2026/0174803 A1City of Hope
Most cited
By later US patents
- Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use239US 5,176,996 ABaylor College of Medicine · 1993
- Nucleic acids and proteins from streptococcus groups A and B59US 9,738,693 B2J. Craig Venter Institute, Inc. · 2017
- Nucleic acids and proteins from Streptococcus groups A and B59US 9,840,538 B2J. Craig Venter Institute, Inc. · 2017
- Nucleic acids and proteins from Streptococcus groups A & B26US 7,939,087 B2Novartis Vaccines and Diagnostics, Inc. · 2011
- Fusion proteins of collagen-binding domain and parathyroid hormone12US 8,450,273 B2Board of Trustees of the University of Arkansas · 2013